Sveikatistė - Company finances
|
EUR
|
2022
From: 2022-07-08
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 0 | - | 9,070 | 43,837 |
| Profit before tax | 0 | -1 | 0 | 0 |
| Net profit | 0 | -1 | 0 | 0 |
| Equity | 1 | 0 | 0 | 0 |
| Liabilities | 0 | 0 | 0 | 0 |
| Non-current assets | 0 | 0 | 0 | 0 |
| Current assets | 1 | 0 | 0 | 0 |
| Total assets | 1 | 0 | 0 | 0 |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | - | +383.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | - | - | - |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | 0.0% | 0.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 0.0% | 0.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Sveikatistė - Social security debts
The company had no debts to Sodra
Sveikatistė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Sveikatiste, MB (code 306112703) is a Lithuanian small partnership engaged in general medical practice activities. In the latest financial year, 2025, the company reported revenue of €43.8K, compared with €9.1K in 2024, indicating strong year-on-year growth of 383.3%. The revenue trajectory therefore points to a marked expansion in operating scale over the two available reporting years. Profitability information is limited, but the company recorded a minimal net loss of €1 in 2023, suggesting results were close to break-even at that time. No further profit figures are provided for 2024 or 2025, so the latest performance assessment is based mainly on revenue development. Overall, the available data show a small medical services business that moved from modest turnover in 2024 to materially higher revenue in 2025, while historical profitability remained around break-even. As a small partnership, its financial profile remains relatively lean and focused on general medical practice operations.